Alivus Life Sciences Q1 FY27: Non-GPL strength offsets GPL dip as margins expand

Alivus Life Sciences began FY27 with a quarter that looked ordinary on topline growth but unusually strong on profitability. For Q1 FY27, revenue from operations rose to INR 640.4 crore, up 6.4% year on year, even though the company’s GPL-linked revenues fell sharply due to inventory rationalization. The more important shift was in margins: gross margin improved to 60.2% and EBITDA margin expanded to 36.6%, lifting EBITDA to INR 234.1 crore and PAT to INR 160.1 crore.

Management positioned the quarter as evidence of a more resilient and diversified revenue base. The non-GPL portfolio continued to scale across geographies, while newly launched products and operational efficiencies supported profitability. The company also reported free cash flow of INR 90.1 crore and cash and cash equivalents including short-term investments of INR 880.2 crore as of June 30, 2026, alongside a debt-free balance sheet.

The quarter in numbers: steady revenue, sharp step-up in profitability

The key financial feature of Q1 FY27 was the margin profile. Gross profit rose faster than revenue, supported by a product mix tilted toward newer launches. EBITDA grew 29.1% year on year, far outpacing revenue growth, and PAT increased 31.8%.

Management said the two main drivers behind the higher gross margin were new launches and operational efficiency. In the earnings call, the CEO also addressed the sustainability question directly, saying gross margins should broadly hold with some quarter-to-quarter movement.

Mix shift: Non-GPL accelerates while GPL resets

The quarter’s key operating storyline was the divergence between GPL and non-GPL businesses. GPL revenues dropped to INR 72.3 crore in Q1 FY27, only 11.3% of total revenue, representing a 52.6% year-on-year decline. Management attributed this to inventory rationalization and emphasized that GPL is typically skewed toward the second half of the year. For FY27, management expects the GPL business to be flattish overall, with a stronger H2.

In contrast, non-GPL revenue climbed to INR 568.1 crore, 88.7% of total revenue. The company reported 26.5% year-on-year growth and 27.6% sequential growth in non-GPL, supported by healthy demand across geographies and rising contribution from recently launched products.

This mix shift also mattered for profitability. In the Q&A, management acknowledged that non-GPL is more margin accretive than GPL. At the same time, the CFO indicated that if GPL volumes recover, the blended EBITDA margin could normalize from the current 36.6% to closer to about 34% in a steadier state, which aligns with the company’s decision to retain a conservative EBITDA margin guidance for the year.

Segment picture: Generic API dominates; CDMO remains small but watchable

By segment, Generic API remained the dominant business line. In Q1 FY27, Generic API revenue was INR 592.1 crore, about 94% of total revenue, and grew 7.4% year on year. CDMO revenue was INR 37.8 crore, about 6% of total revenue, and grew 3.8% year on year.

Management reiterated that CDMO is inherently lumpy and can vary quarter to quarter. The company expects stronger CDMO momentum in H2 FY27, supported by contributions from newly added projects. In the call, management stated it has ongoing revenue coming from five projects and is in active discussions on about seven projects. They also confirmed that two brand-new CDMO contracts expected in early H2 FY27 remain on track.

Guidance and execution priorities: growth skewed to H2, margins guided conservatively

Management provided explicit FY27 guidance: revenue growth of 10% to 12% and EBITDA margins of 30% to 32%. In the earnings call, the CEO said the company could potentially guide to better margins, even up to about 34%, but chose to stay cautious due to the war situation and its potential impact on raw material costs. Management noted that raw material prices have increased and that the company has passed on part of the increase to customers, though not across the board.

On growth, management emphasized that the non-GPL momentum is expected to continue, supported by recent launches and a robust pipeline. One investor question probed how much of non-GPL growth was price versus volume. The CFO responded that the non-GPL year-on-year growth included about a 7% foreign exchange impact; on a constant currency basis, growth was about 20%, with volume growth around 21% to 22% and price decline of about 1% to 2%.

Capacity, R&D and pipeline: calibrated capex with new sites progressing

Alivus continues to invest in capacity and R&D, but management described its approach as calibrated. The presentation highlights a brownfield capacity addition plan at Dahej and Ankleshwar, alongside a greenfield expansion at Solapur.

The capacity plan includes a brownfield addition of about 160 KL at Dahej, targeted for Q3 FY27, and about 100 KL at Ankleshwar, targeted for Q4 FY27. For Solapur, the plan includes Phase 1 of about 350 KL and Phase 2 of about 115 KL, with Phase 3 planned later. In the earnings call, management said Solapur is slightly delayed but expected to be operational in early Q3 FY27, with products already mapped for initial loading. They also noted that Solapur will initially support ROW business for about a year until major agency inspections enable regulated-market production.

R&D intensity continues to move up. Q1 FY27 R&D spending was INR 23.7 crore, or 3.7% of revenue. Management stated R&D spend should settle around 4% in steady state, and clarified that the focus is largely API development and next-generation processes, with some CDMO analytical and regulatory support.

The presentation also highlights the company’s development and filing footprint, stating cumulative DMF and CEP filings reached 617 as of June 30, 2026. It also notes progress in complex platforms. The high-potent API portfolio has 29 products in the active development grid with a stated TAM of about INR 82 billion (IQVIA, MAT Mar 2026). For iron complexes, the company said regulatory filing has been completed for one iron compound, with one validated product and another in advanced development.

Takeaways

Q1 FY27 underscored the company’s shift away from dependence on GPL toward a broader, faster-growing non-GPL portfolio. The quarter delivered a strong step-up in profitability, with gross margin at 60.2% and EBITDA margin at 36.6%. Management is guiding for 10% to 12% revenue growth in FY27, with growth skewed to H2, and EBITDA margins of 30% to 32% on a conservative basis.

The near-term variables remain clear. GPL recovery in H2 will influence mix and blended margins, CDMO growth can be uneven quarter to quarter, and geopolitical volatility could pressure raw material prices. Against this backdrop, the company’s execution focus is on sustaining launch momentum, commissioning new capacity in a calibrated manner, and continuing pipeline investment, while maintaining a debt-free balance sheet and strong cash position.